The epidemiology of hepatitis C among injecting drug users in Belgium

Acta Gastro-Enterologica Belgica

Volumn 68, Issue 1, 2005, Pages 50-54

  Matheï, Catharina ^a   Robaeys, G ^b   Van Ranst, M ^a   Van Damme, P ^c   Buntinx, F ^a,d  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF CARDIOLOGY   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Epidemiology; HCV RNA; Hepatitis C; Hepatitis C genotypes; Injecting drug users

Indexed keywords

HEPATITIS C ANTIBODY; VIRUS RNA;

BELGIUM; COMPARATIVE STUDY; CONFERENCE PAPER; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; PREVALENCE; SUBSTANCE ABUSE; SUPERINFECTION; SYSTEMATIC REVIEW; VIRUS CARRIER; WESTERN EUROPE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; BELGIUM; COMORBIDITY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PRIMARY PREVENTION; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SUBSTANCE ABUSE, INTRAVENOUS; SURVIVAL ANALYSIS;

EID: 16444364456     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (56)

1. Hepatitis C: global prevalence. Wkly. Epidemiol. Rec., 1997, 72: 341-344.
2. VAN DAMME P., THYSSEN A., VAN LOOCK F. Epidemiology of hepatitis C in Belgium: present and future. Acta Gastroenterol. Belg., 2002, 65: 78-79.
3. THOMAS D.L., CANNON R.O., SHAPIRO C.N., HOOK E.W., ALTER M.J., QUINN T.C. Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. J. Infect. Dis., 1994, 169: 990-995.
4. HAGAN H., THIEDE H., WEISS N.S., HOPKINS S.G., DUCHIN J.S., ALEXANDER E.R. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am. J. Public Health, 2001, 91: 42-46.
5. CROFTS N., JOLLEY D., KALDOR J., VAN BEEK I., WODAK A. Epidemiology of hepatitis C virus infection among injecting drug users in Australia. J. Epidemiol. Community Health, 1997, 51: 692-697.
6. DENIS B., DEDOBBELEER M., COLLET T., PETIT J., JAMOULLE M., HAYANI A. et al. High prevalence of hepatitis C virus infection in Belgian intravenous drug users and potential role of the "cotton-filter" in transmission: the GEMT Study. Acta Gastroenterol. Belg., 2000, 63: 147-153.
7. MATHEI C., BUNTINX F., VAN DAMME P. Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: a systematic review. J. Viral Hepat., 2002, 9: 157-173.
8. REISS G., KEEFFE E.B. Review article: hepatitis vaccination in patients with chronic liver disease. Aliment. Pharmacol. Ther., 2004, 19: 715-727.
9. MATHEWS G., BHAGANI S. The epidemiology and natural history of HIV/HBV and HIV/HCV co-infections. J. HIV Ther., 2003, 8; 77-84.
10. GARFEIN R.S., VLAHOV D., GALAI N., DOHERTY M.C., NELSON K.E. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am. J. Public Health, 1996, 86: 655-661.
11. KURBANOV F., TANAKA Y., SUGAUCHI F., KATO H., RUZIBAKIEV R., ZALYALIEVA M. et al. Hepatitis C virus molecular epidemiology in Uzbekistan. J. Med. Virol., 2003, 69: 367-375..
12. VANDERSCHUEREN S., VAN RENTERGHEM L., PLUM J., VERHOFSTEDE C., MAK R., VINCKE J. Hepatitis C among risk groups for HIV and hepatitis B. Int. J. STD. AIDS. 1991, 2: 185-187.
13. BUTLER T., SPENCER J., CUI J., VICKERY K., ZOU J., KALDOR J. Seroprevalence of markers for hepatitis B, C and G in male and female prisoners - NSW, 1996. Aust. N. Z. J. Public Health, 1999, 23: 377-384.
14. SCHLICTING E.G., JOHNSON M.E., BREMS C., WELLS R.S., FISHER D.G., REYNOLDS G. Validity of injecting drug users' self report of hepatitis A, B, and C. Clin. Lab. Sci., 2003, 16: 99-106.
15. MATHEI C., ROBAEYS G., VAN DAMME P., BUNTINX F., VERRANDO R. Prevalence of Hepatitis C in drug users in Flanders: determinants and geographic differences. Epidemiol. Infect., 2005 (in press).
16. VENTO S., GAROFANO T., RENZINI C., CAINELLI F., CASALI F., GHIRONZI G. et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N. Engl. J. Med., 1998, 338: 286-290.
17. AKRIVIADIS E.A., REDEKER A.G. Fulminant hepatitis A in intravenous drug users with chronic liver disease. Ann. Intern. Med., 1989, 110: 838-839.
18. OCHNIO J.J., PATRICK D., HO M., TALLING D.N., DOBSON S.R. Past infection with hepatitis A virus among Vancouver street youth, injection drug users and men who have sex with men: implications for vaccination programs. CMAJ, 2001, 165: 293-297.
19. CROFTS N., COOPER G., STEWART T., KIELY P., COGHLAN P., HEARNE P. et al. Exposure to hepatitis A virus among blood donors, injecting drug users and prison entrants in Victoria. J. Viral Hepat., 1997, 4: 333-338.
20. VILLANO S.A., NELSON K.E., VLAHOV D., PURCELL R.H., SAAH A.J., THOMAS D.L. Hepatitis A among homosexual men and injection drug users: more evidence for vaccination. Clin. Infect. Dis., 1997, 25: 726-728.
21. HARKESS J., GILDON B., ISTRE G.R. Outbreaks of hepatitis A among illicit drug users, Oklahoma, 1984-87. Am. J. Public Health, 1989, 79: 463-466.
22. SYED N.A., HEARING S.D., SHAW I.S., PROBERT C.S., BROOKLYN T.N., CAUL E.O. et al. Outbreak of hepatitis A in the injecting drug user and homeless populations in Bristol: control by a targeted vaccination programme and possible parenteral transmission. Eur. J. Gastroenterol. Hepatol., 2003, 15: 901-906.
23. O'DONOVAN D., COOKE R.P., JOCE R., EASTBURY A., WAITE J., STENE-JOHANSEN K. An outbreak of hepatitis A amongst injecting drug users. Epidemiol. Infect., 2001, 127: 469-473.
24. MATHEI C., ROBAEYS G., VAN RANST M., VAN DAMME P., BUNTINX F. Molecular epidemiology of hepatitis C among drug users, correlation with clinical parameters, sexual behaviour and drug-related risk behaviour. 14th European Congress of Clinical microbiology and Infectious Diseases. Abstract P1575. 2004. Blackwell Publishing.
25. MATHEI C., BUNTINX F., VAN DAMME P. Is the prevalence of hepatitis C virus (HCV) RNA in anti-HCV-positive injection drug users positively correlated with age? J. Infect. Dis., 2001, 184: 659-660.
26. RODGER A.J., ROBERTS S., LANIGAN A., BOWDEN S., BROWN T., CROFTS N. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology, 2000, 32: 582-587.
27. HARRIS K.A., GILHAM C., MORTIMER P.P., TEO C.G. The most prevalent hepatitis C virus genotypes in England and Wales are 3a and 1a. J. Med. Virol., 1999, 58: 127-131.
28. POHJANPELTO P., LAPPALAINEN M., WIDELL A., ASIKAINEN K., PAUNIO M. Hepatitis C genotypes in Finland determined by RFLP. Clin. Diagn. Virol., 1996, 7: 7-16.
29. BOURLIERE M., BARBERIN J.M., ROTILY M., GUAGLIARDO V., PORTAL I., LECOMTE L. et al. Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users. J. Viral Hepat., 2002, 9: 62-70.
30. ELGHOUZZI M.H., BOUCHARDEAU F., PILLONEL J., BOIRET E., TIRTAINE C., BARLET V. et al. Hepatitis C virus: routes of infection and genotypes in a cohort of anti-HCV-positive French blood donors. Vox Sang., 2000, 79: 138-144.
31. STARK K., SCHREIER E., MULLER R., WIRTH D., DRIESEL G., BIENZLE U. Prevalence and determinants of anti-HCV seropositivity and of HCV genotype among intravenous drug users in Berlin. Scand. J. Infect. Dis., 1995, 27: 331-337.
32. BERG T., HOPF U., STARK K., BAUMGARTEN R., LOBECK H., SCHREIER E. Distribution of hepatitis C virus genotypes in German patients with chronic hepatitis C: correlation with clinical and virological parameters. J. Hepatol., 1997, 26: 484-491.
33. GOESER T., SEIPP S., WAHL R., MULLER HM., STREMMEL W., THEILMANN L. Clinical presentation of GB-C virus infection in drug abusers with chronic hepatitis C. J. Hepatol., 1997, 26: 498-502.
34. ROSS R.S., VIAZOV S., RENZING-KOHLER K., ROGGENDORF M. Changes in the epidemiology of hepatitis C infection in Germany: shift in the predominance of hepatitis C subtypes. J. Med. Virol., 2000, 60: 122-125.
35. DRIESEL G., WIRTH D., STARK K., BAUMGARTEN R., SUCKER U., SCHREIER E. Hepatitis C virus (HCV) genotype distribution in German isolates: studies on the sequence variability in the E2 and NS5 region. Arch. Virol., 1994, 139: 379-388.
36. DAL MOLIN G., ANSALDI F., BIAGI C., D'AGARO P., COMAR M., CROCE L. et al. Changing molecular epidemiology of hepatitis C virus infection in Northeast Italy. J. Med. Virol., 2002, 68: 352-356.
37. TONIUTTO P., FALLETI E., GASPARINI V., FABRIS C., TISMINETZKY S.G., LOMBARDELLI T. et al. IgM antibody response to the hepatitis C virus core protein in intravenous drug users. Diagn. Microbiol. Infect. Dis., 1999, 33: 69-73.
38. VITALE F., VILLAFRATE M.R., VIVIANO E., PERNA A.M., BONURA F., DI BENEDETTO M.A. et al. Distribution of hepatitis C virus genotypes among intravenous drug users. A ten-year study in Palermo, Sicily. New Microbiol., 1998, 21: 335-342.
39. PIRISI M., TONIUTTO P., FABRIS C., LOMBARDELLI T., FALLETI E., TISMINETZKY S.G. et al. Factors associated with serum HCV RNA positivity in anti-HCV antibody positive intravenous drug users. J. Clin. Epidemiol., 1998, 51: 423-427.
40. SILINI E., BONO F., CIVIDINI A., CERINO A., MACCABRUNI A., TINELLI C. et al. Molecular epidemiology of hepatitis C virus infection among intravenous drug users. J. Hepatol., 1995, 22: 691-695.
41. SEMPRINI A.E., PERSICO T., THIERS V., ONETA M., TUVERI R., SERAFINI P. et al. Absence of hepatitis C virus and detection of hepatitis G virus/GB virus C RNA sequences in the semen of infected men. J. Infect. Dis., 1998, 177: 848-854.
42. SARACCO G., SOSTEGNI R., GHISETTI V., ROCCA G., CARITI G., ANDREONI M. et al. Hepatitis C virus genotypes in a non-cirrhotic Italian population with chronic hepatitis C: correlation with clinical, virological and histological parameters. Results of a prospective multicentre study. J. Viral Hepat., 2000, 7: 124-129.
43. CILLA G., GARCIA-BENGOECHEA M., PEREZ-TRALLERO E., MONTALVO I., VICENTE D., ARENAS J.I. Genotyping of hepatitis C virus isolates from Basque Country, Spain. Epidemiol. Infect., 1996, 117: 533-536.
44. BRAVO R., SORIANO V., GARCIA-SAMANIEGO J., GONZALEZ J., CASTRO A., COLMENERO M. et al. [Prevalence of the genotypes of the hepatitis C virus in Spanish drug addicts with chronic hepatitis C. Spanish Group for the Study of Viral Hepatitis in HIV Positive Patients]. Rev. Clin. Esp., 1996, 196: 673-677.
45. TOUCEDA S., PEREIRA M., AGULLA A. [Prevalence of hepatitis C virus genotypes in the area of El Ferrol (La Coruna, Spain)]. Enferm. Infecc. Microbiol. Clin., 2002, 20: 200-204.
46. WESTIN J., LINDH M., LAGGING L.M., NORKRANS G., WEJSTAL R. Chronic hepatitis C in Sweden: genotype distribution over time in different epidemiological settings. Scand. J. Infect. Dis., 1999, 31: 355-358.
47. DIAMANTIS I., BASSETTI S., ERB P., LADEWIG D., GYR K., BATTEGAY M. High prevalence and coinfection rate of hepatitis G and C infections in intravenous drug addicts. J. Hepatol., 1997, 26: 794-797.
48. ROBAEYS G., VAN VLIERBERGHE H., MATHEI C., VAN RANST M., BRUCKERS L., BUNTINX F. Compliance and effect of treatment for chronic hepatitis C (CHC) in intravenous drug users (IVDUs). J. Hepatol., 2003, 38 (Suppl): 165.
49. HAHN J.A., PAGE-SHAFER K., LUM P.J., OCHOA K., MOSS A.R. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology, 2001, 34: 180-187.
50. DENIS B., HAYANI A., JAMOULLE M., PASTEGER D., SEGERS J.-M., PETIT J. et al. Toxicomanie el virus de l'hépatite C, B et HIV. Bulletin de l'Hôpital Civil de Charleroi, 2004, 44: 209-213.
51. MAJID A., HOLMES R., DESSELBERGER U., SIMMONDS P., MCKEE T.A. Molecular epidemiology of hepatitis C virus infection amongst intravenous drug users in rural communities. J. Med. Virol., 1995, 46: 48-51.
52. STARK K., SCHREIER E., MULLER R., WIRTH D., DRIESEL G., BIENZLE U. Prevalence and determinants of anti-HCV seropositivity and of HCV genotype among intravenous drug users in Berlin. Scand. J. Infect. Dis., 1995, 27: 331-337.
53. ANASTASSOPOULOU C.G., PARASKEVIS D., SYPSA V., PSICHOGIOU M., KATSOULIDOU A., TASSOPOULOS N. et al. Prevalence patterns and genotypes of GB virus C/hepatitis G virus among imprisoned intravenous drug users. J. Med. Virol., 1998, 56: 246-252.
54. LOVE A., SIGURDSSON J.R., STANZEIT B., BRIEM H., RIKARDSDOTTIR H., WIDELL A. Characteristics of hepatitis C virus among intravenous drug users in Iceland. Am. J. Epidemiol., 1996, 143: 631-636.
55. COPPOLA R.C., MASIA G., DI MARTINO M.L., CARBONI G., MUGGIANU E., PIRO R. et al. Sexual behaviour and multiple infections in drug abusers. Eur. J. Epidemiol., 1996, 12: 429-435.
56. ROY K.M., BAGG J., MCCARRON B., GOOD T., CAMERON S., PITHIE A. Predominance of HCV type 2a in saliva from intravenous drug users. J. Med. Virol., 1998, 54: 271-275.